NewAmsterdam Pharma Company N.V. Ordinary Shares

NAMSNASDAQ • USD
19.69 USD
↘ 0.45 (2.24%)🟢LIVE (AS OF 02:00 PM EST)
🟢Market: OPEN

Shares of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) are trading at $19.69. Our models show a "Sell" technical signal alongside a "Neutral" fundamental rating. Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 2/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Furthermore, NAMS is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Nov 13, 2026.

Open?$19.94
High?$21.49
Low?$18.45
Prev. Close?$20.14
Volume?599.6K
Avg. Volume?1.6M
VWAP?$20.07
Rel. Volume?0.37x
Bid / Ask
Bid?$19.06 × 100
Ask?$22.65 × 100
Spread?$3.59
Midpoint?$20.85
Valuation & Ratios
Market Cap?2.4B
Shares Out?119.9M
Float?86.2M
Float %?72.1%
P/E Ratio?N/A
P/B Ratio?3.83
EPS?-$1.71
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Employees
100
Market Cap
2.4B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2022-11-23
Address
GOOIMEER 2-35
NARRDEN, P7 1411 DC
Phone: 35 206 2971
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
100
Momentum?
83
Short Sent.?
59
Piotroski F-Score?2/9Weak
Altman Z-Score?23.51Safe
Confidence?55%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?13.93%High
Short Interest?12.0M
Days to Cover?8.3
Free Float86.2M
Avg Daily Volume1.4M
Settlement Date2026-10-30
Financial Health
Current Ratio?11.76Strong
Quick Ratio?11.76Strong
Cash Ratio?7.40Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
46
3.83FAIR▾
P/S?
Peers
100
S&P
3
93.13HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-8.5CHEAP▾
EV/Sales?
Peers
100
S&P
3
76.81HIGH▾
Returns & Efficiency
ROE?
S&P
6
-32.5%WEAK▾
ROA?
S&P
3
-29.8%WEAK▾
Cash Flow & Enterprise
FCF?$-150861000
Enterprise Value?$2.0B
Fundamentals ratios updated end of day